ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ ΥΠΟΥΡΓΕΙΟ ΕΜΠΟΡΙΟΥ, ΒΙΟΜΗΧΑΝΙΑΣ ΚΑΙ ΤΟΥΡΙΣΜΟΥ

First Page		Document Content
Date: 2013-05-10 02:37:31 Immunology Treatment of multiple sclerosis Glatiramer acetate Swank diet Natalizumab Neurology Interferon Amyotrophic lateral sclerosis Remyelination Multiple sclerosis Medicine Health		ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ ΥΠΟΥΡΓΕΙΟ ΕΜΠΟΡΙΟΥ, ΒΙΟΜΗΧΑΝΙΑΣ ΚΑΙ ΤΟΥΡΙΣΜΟΥ Add to Reading List Source URL: www.cing.ac.cy Download Document from Source Website File Size: 384,70 KB Share Document on Facebook

	PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno DocID: 1vlwz - View Document
	IMPORTANT PLEASE READ PART III: CONSUMER INFORMATION INTRON A® interferon alfa-2b This leaflet is part III of a three-part "Product Monograph" DocID: 1uNBi - View Document
	Evaluation of Interferon-gamma-Producing T Cells DocID: 1uFKZ - View Document
	PRODUCT MONOGRAPH INTRON A® interferon alfa-2b Lyophilized Powder with Diluent: 10 million IU interferon alfa-2b/vial DocID: 1umTG - View Document
	  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg) DocID: 1u1rK - View Document